Syncona Shares Rise After Beacon's Gene Therapy for Rare Eye Disease Succeeds in Late-Stage Trial

Shares in Syncona (LSE:SYNC) jumped approximately 6% on Monday following an announcement from its portfolio company, Beacon Therapeutics, that a late-stage trial for its gene therapy candidate successfully met its primary endpoint. The positive data paves the way for the company to begin discussions with global regulators for potential market approval.

Key Trial Results

Beacon Therapeutics reported that its VISTA trial for laruparetigene zovaparvovec (laru-zova) achieved its primary goal with statistical significance. The therapy is being developed to treat X-linked retinitis pigmentosa (XLRP), a rare inherited disease that causes progressive vision loss.

The 12-month study evaluated 85 male patients. According to the company's statement:

• 31% of patients receiving a high dose and 24.1% of those on a low dose showed a clinically meaningful improvement in low-luminance visual acuity.
• This compared to 0% of patients in the untreated control group, a result that was statistically significant (p-values of 0.0019 and 0.0106, respectively).

Ad

Beacon also noted that most ocular adverse events were mild to moderate and generally attributed to the surgical procedure rather than the therapy itself. Treatment-related adverse events occurred in 25% of high-dose patients and 38% of low-dose patients.

Path to Market

The successful trial outcome is a critical milestone for Beacon Therapeutics. The company announced it plans to initiate discussions with global regulatory bodies, including the U.S. Food and Drug Administration (FDA).

Beacon intends to begin a rolling Biologics License Application (BLA) submission to the FDA later this year. It is important to note that laru-zova remains an investigational therapy and has not yet been approved for commercial use by any regulatory authority.